Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest autoimmune disease Stories

2013-10-31 08:31:45

SANTA BARBARA, Calif., Oct. 31, 2013 /PRNewswire/ -- VG Life Sciences, Inc. is a publicly traded (VGLS) biotechnology company focused on developing treatments for patients suffering autoimmune and infectious diseases. (Logo: http://photos.prnewswire.com/prnh/20131031/LA07859LOGO) The United States Patent and Trademark Office has issued on October 15, 2013 Patent No.: US 8,557,764 covering the VG Life Sciences' peptide VG1177 for treating HIV infection. The VG1177 peptide prevents...

2013-10-30 12:26:11

CLEARWATER, Florida, October 30, 2013 /PRNewswire/ -- Daval International, the emerging life sciences company focused on the development of novel treatments for serious unmet medical needs, presented a poster at the 12th Annual Meeting of the North East ALS (NEALS) Consortium which took place 3rd-4th October 2013, at the Sandpearl Resort, Clearwater Beach, FL, USA. The poster was entitled "1H-MRS & FDG-PET studies in the SOD1 G93A - the use of stabilized peptides as a...

2013-10-02 08:28:17

SANTA BARBARA, Calif., Oct. 2, 2013 /PRNewswire/ -- VG Life Sciences, Inc. (VGLS) is a publicly traded biotechnology company focused on delivering treatments for patients suffering from autoimmune and chronic inflammatory disorders. VG Life Sciences is pleased to announce the closing of a significant capital event. MedBridge Venture Fund, LLC has made a cash investment in the Company of $2,235,000. This is in addition to the $550,000 cash investment made by MedBridge, LLC in...

2013-09-26 08:27:17

Frost & Sullivan: Hospitals and laboratories look for cost-effective test panels enabling simultaneous autoimmune diseases testing MOUNTAIN VIEW, Calif., Sept. 26, 2013 /PRNewswire/ -- Successful autoimmune disease awareness campaigns are encouraging patients to seek clinical diagnostics even for general symptoms such as fatigue and gastrointestinal distress, spurring the global autoimmune disease diagnostics market. The rising incidence of gastrointestinal autoimmune conditions, primarily...

2013-09-10 11:09:13

UCSF experiments halt pancreas destruction in mouse model of diabetes Scientists from UC San Francisco have identified a new way to manipulate the immune system that may keep it from attacking the body’s own molecules in autoimmune diseases such as type 1 diabetes, rheumatoid arthritis and multiple sclerosis. The researchers, led by immunologist Mark Anderson, MD, PhD, a professor with the UCSF Diabetes Center, have discovered a distinctive type of immune cell called an eTAC, which...

2013-09-03 16:27:48

PETACH TIKVA, Israel, Sept. 3, 2013 /PRNewswire/ -- OphthaliX Inc. (OTC BB: OPLID), announced today that the European Patent Office issued a Certificate of Grant of Patent for European Patent No. 1778239 entitled "Adenosine A3 receptor agonists for the treatment of dry eye disorders including Sjogren's syndrome". This patent was granted to OphthaliX's parent and majority stockholder, Can-Fite BioPharma Ltd., and relates to OphthaliX's drug candidate CF101. Pursuant to the license...

2013-08-27 23:04:06

Hundreds of medical professionals from a variety of specialties, convened at the JW Marriott- LA Live last weekend, August 16th and 17th, to extend their medical education. Boca Raton, FL (PRWEB) August 27, 2013 The main objective of the course was to inform practitioners on the relationship between food and the manifestation of diseases into the body and how to better their patients’ overall well-being. The two-day symposium featured several expert medical faculty who presented...

2013-07-29 08:25:53

SAN DIEGO, July 29, 2013 /PRNewswire/ -- aTyr Pharma, an innovative protein therapeutics enterprise focused on rare diseases, announced today the close of $10 million debt financing from Silicon Valley Bank to support the clinical development of aTyr's first therapeutic program to treat rare autoimmune diseases and a rare disease pipeline in immune disorders. (Logo: http://photos.prnewswire.com/prnh/20120809/MM55538LOGO) "In conjunction with our Series D financing, this loan...

2013-07-29 08:25:51

SAN DIEGO, July 29, 2013 /PRNewswire/ -- aTyr Pharma, an innovative protein therapeutics enterprise focused on rare diseases, announced today the successful completion of a $49 million financing. A premier, global public investment fund joined existing investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Partners in the equity financing. The financing supports the clinical development of aTyr's first therapeutic program to treat rare autoimmune diseases and a rare...

2013-07-17 16:27:42

AbGenomics raised new fund for advancing its clinical trials and new linker-payload technology LOS ALTOS, Calif., July 17, 2013 /PRNewswire-iReach/ -- AbGenomics International announced today that it has raised $9.6 million in current financing round. (Photo: http://photos.prnewswire.com/prnh/20130717/MN49038) AbGenomics will use the proceeds to continue advancing its therapeutic antibodies for autoimmune diseases and cancers. AbGenomics' lead drug candidate AbGn-168H, a...